Preclinical Characterization of the Antiviral Activity of SCH 900518 (Narlaprevir), a Novel Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease

被引:30
作者
Tong, X. [1 ]
Arasappan, A. [2 ]
Bennett, F. [2 ]
Chase, R. [1 ]
Feld, B. [1 ]
Guo, Z. [3 ]
Hart, A. [1 ]
Madison, V. [3 ]
Malcolm, B. [1 ]
Pichardo, J. [1 ]
Prongay, A. [3 ]
Ralston, R. [1 ]
Skelton, A. [1 ]
Xia, E. [1 ]
Zhang, R. [4 ]
Njoroge, F. G. [2 ]
机构
[1] Schering Plough Res Inst, Dept Virol, Kenilworth, NJ 07033 USA
[2] Schering Plough Res Inst, Dept Med Chem, Kenilworth, NJ 07033 USA
[3] Schering Plough Res Inst, Dept Struct Chem, Kenilworth, NJ 07033 USA
[4] Schering Plough Res Inst, Dept New Lead Discovery, Kenilworth, NJ 07033 USA
关键词
HCV PROTEASE; RESISTANCE MUTATIONS; PLUS RIBAVIRIN; SCH-503034; BINDING; INTERFERON-ALPHA-2B; COMBINATION; MONOTHERAPY; VARIANTS; VX-950;
D O I
10.1128/AAC.00135-10
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Small-molecule hepatitis C virus (HCV) NS3 protease inhibitors such as boceprevir (SCH 503034) have been shown to have antiviral activity when they are used as monotherapy and in combination with pegylated alpha interferon and ribavirin in clinical trials. Improvements in inhibitor potency and pharmacokinetic properties offer opportunities to increase drug exposure and to further increase the sustained virological response. Exploration of the structure-activity relationships of ketoamide inhibitors related to boceprevir has led to the discovery of SCH 900518, a novel ketoamide protease inhibitor which forms a reversible covalent bond with the active-site serine. It has an overall inhibition constant (K-i*) of 7 nM and a dissociation half-life of 1 to 2 h. SCH 900518 inhibited replicon RNA at a 90% effective concentration (EC90) of 40 nM. In biochemical assays, SCH 900518 was active against proteases of genotypes 1 to 3. A 2-week treatment with 5 x EC90 of the inhibitor reduced the replicon RNA level by 3 log units. Selection of replicon cells with SCH 900518 resulted in the outgrowth of several resistant mutants ( with the T54A/S and A156S/T/V mutations). Cross-resistance studies demonstrated that the majority of mutations for resistance to boceprevir and telaprevir caused similar fold losses of activity against all three inhibitors; however, SCH 900518 retained more activity against these mutants due to its higher intrinsic potency. Combination treatment with alpha interferon enhanced the inhibition of replicon RNA and suppressed the emergence of resistant replicon colonies, supporting the use of SCH 900518-pegylated alpha interferon combination therapy in the clinic. In summary, the results of the preclinical characterization of the antiviral activity of SCH 900518 support its evaluation in clinical studies.
引用
收藏
页码:2365 / 2370
页数:6
相关论文
共 30 条
[1]   Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor [J].
Arasappan, Ashok ;
Bennett, Frank ;
Bogen, Stephane L. ;
Venkatraman, Srikanth ;
Blackman, Melissa ;
Chen, Kevin X. ;
Hendrata, Siska ;
Huang, Yuhua ;
Huelgas, Regina M. ;
Nair, Latha ;
Padilla, Angela I. ;
Pan, Weidong ;
Pike, Russell ;
Pinto, Patrick ;
Ruan, Sumei ;
Sannigrahi, Mousumi ;
Velazquez, Francisco ;
Vibulbhan, Bancha ;
Wu, Wanli ;
Yang, Weiying ;
Saksena, Anil K. ;
Girijavallabhan, Viyyoor ;
Shih, Neng-Yang ;
Kong, Jianshe ;
Meng, Tao ;
Jin, Yan ;
Wong, Jesse ;
McNamara, Paul ;
Prongay, Andrew ;
Madison, Vincent ;
Piwinski, John J. ;
Cheng, Kuo-Chi ;
Morrison, Richard ;
Malcolm, Bruce ;
Tong, Xiao ;
Ralston, Robert ;
Njoroge, F. George .
ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (02) :64-69
[2]  
Beyer BM, 2001, PROTEINS, V43, P82, DOI 10.1002/1097-0134(20010501)43:2<82::AID-PROT1020>3.0.CO
[3]  
2-4
[4]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[5]   Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].
Fried, MW ;
Shiffman, ML ;
Reddy, KR ;
Smith, C ;
Marinos, G ;
Goncales, FL ;
Haussinger, D ;
Diago, M ;
Carosi, G ;
Dhumeaux, D ;
Craxi, A ;
Lin, A ;
Hoffman, J ;
Yu, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982
[6]   Computational study of the effects of mutations A156T, D168V, and D168Q on the binding of HCV protease inhibitors [J].
Guo, Zhuyan ;
Prongay, Andrew ;
Tong, Xiao ;
Fischmann, Thierry ;
Bogen, Stephane ;
Velazquez, Francisco ;
Venkatraman, Srikanth ;
Njoroge, F. George ;
Madison, Vincent .
JOURNAL OF CHEMICAL THEORY AND COMPUTATION, 2006, 2 (06) :1657-1663
[7]   Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo [J].
Kolykhalov, AA ;
Mihalik, K ;
Feinstone, SM ;
Rice, CM .
JOURNAL OF VIROLOGY, 2000, 74 (04) :2046-2051
[8]   HCV SPRINT-1 FINAL RESULTS: SVR 24 FROM A PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRON™ (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C [J].
Kwo, P. ;
Lawitz, E. ;
McCone, J. ;
Schiff, E. ;
Vierling, J. ;
Pound, D. ;
Davis, M. ;
Galati, J. ;
Gordon, S. ;
Ravendhran, N. ;
Rossaro, L. ;
Anderson, F. ;
Jacobson, I. ;
Rubin, R. ;
Koury, K. ;
Brass, C. ;
Chaudhri, E. ;
Albrecht, J. .
JOURNAL OF HEPATOLOGY, 2009, 50 :S4-S4
[9]   An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus [J].
Lamarre, D ;
Anderson, PC ;
Bailey, M ;
Beaulieu, P ;
Bolger, G ;
Bonneau, P ;
Bös, M ;
Cameron, DR ;
Cartier, M ;
Cordingley, MG ;
Faucher, AM ;
Goudreau, N ;
Kawai, SH ;
Kukolj, G ;
Lagacé, L ;
LaPlante, SR ;
Narjes, H ;
Poupart, MA ;
Rancourt, J ;
Sentjens, RE ;
St George, R ;
Simoneau, B ;
Steinmann, G ;
Thibeault, D ;
Tsantrizos, YS ;
Weldon, SM ;
Yong, CL ;
Llinàs-Brunet, M .
NATURE, 2003, 426 (6963) :186-189
[10]   In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061 - Structural analysis indicates different resistance mechanisms [J].
Lin, C ;
Lin, K ;
Luong, YP ;
Rao, BG ;
Wei, YY ;
Brennan, DL ;
Fulghum, JR ;
Hsiao, HM ;
Ma, S ;
Maxwell, JP ;
Cottrell, KM ;
Perni, RB ;
Gates, CA ;
Kwong, AD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (17) :17508-17514